Study #2021-1124
A Phase II Study of Vibecotamab (XmAb14045) for MRD-Positive AML and MDS after Hypomethylating Agent Failure
MD Anderson Study Status
Enrolling
Treatment Agent
Vibecotamab, Dexamethasone, Acetaminophen, Diphenhydramine
Description
This is a phase II single-center study to evaluate the safety and effectiveness of vibecotamab, a CD3-CD123 bispecific antibody, in patients with acute myeloid leukemia with persistent or recurrent measurable residual disease and in patients with myelodysplastic syndrome that has not responded to or relapsed after conventional therapy
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML, MDS
Study phase:
Phase II
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.